Teva Pharmaceutical Industries (TEVA) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed United Therapeutics (UTHR) over the past year, gaining 95.2% versus a gain of 19.3%. Over five years, TEVA leads with a +304.8% price change compared with +191.3% for UTHR. Teva Pharmaceutical Industries is the larger company by market cap ($45.77 billion vs $22.99 billion), about 2.0 times the size, while United Therapeutics is growing revenue faster (+10.6% vs +4.3%).
On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.7x vs 17.1x for United Therapeutics). United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TEVA | UTHR |
|---|---|---|
| Share price | $39.25 | $535.98 |
| Market cap | $45.77B | $22.99B |
| 1-day change | +0.17% | -1.66% |
| YTD return | +25.54% | +11.85% |
| 1-year return | +95.22% | +19.30% |
| 5-year return | +304.75% | +191.33% |
| P/E ratio (TTM) | 65.41 | 19.20 |
| Forward P/E | 12.70 | 17.14 |
| EPS (TTM) | $0.60 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $17.26B | $3.18B |
| Revenue growth (YoY) | +4.32% | +10.61% |
| Net income (latest FY) | $1.41B | $1.33B |
| Gross margin | 51.79% | 87.92% |
| Operating margin | 12.50% | 46.89% |
| Net margin | 8.17% | 41.94% |
| 52-week high | $40.79 | $609.35 |
| 52-week low | $18.83 | $409.07 |
| Distance from 52-week high | -3.79% | -12.04% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +15.43% | +21.21% |
| Average volume | 5.29M | 655.10K |
| Shares outstanding | 1.17B | 42.89M |
| Employees | 31,173 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TEVA has outperformed UTHR by 75.9 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.4x vs 19.2x trailing P/E).
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus 8.2 cents for Teva Pharmaceutical Industries.
- United Therapeutics grew revenue faster in its latest fiscal year (+10.61% vs +4.32%).
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
TEVA vs UTHR FAQ
Which is bigger, Teva Pharmaceutical Industries or United Therapeutics?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.77B compared with $22.99B for United Therapeutics (UTHR).
Which stock has performed better over the past year, TEVA or UTHR?
TEVA returned +95.22% over the past 12 months, compared with +19.30% for UTHR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, TEVA or UTHR?
UTHR has the lower trailing P/E at 19.2, versus 65.4 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Teva Pharmaceutical Industries and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.